Poland· PL-100125566
Rapilysin
A reteplase product containing reteplasum, registered in Poland by Actavis Group PTC ehf.. The same ATC class is registered in 7 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Reteplase is registered in 7 of 19 countries.
Countries holding a registration under ATC B01AD07 (reteplase), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 3 of them publish a price we can compare per daily dose
Reteplase · ATC B01AD07
7 / 19 countries
- Belgiumprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Reteplasum
- Manufacturer
- Actavis Group PTC ehf.
- Country
- Poland (PL)
- ATC code
- B01AD07
- ATC class
- Reteplase
- Defined daily dose
- 20 E, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909990000593
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
143 interactions on record for reteplase.
Graded by severity as the source publishes them — 49 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Reteplase · interactions on record
143 records
- 49 severe
- 94 moderate
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- DalteparinB01AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Reteplase in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandEcokinaseGalenus Mannheim GmbH
- BelgiumRapilysin 10 UActavis Group PTC
- SpainRAPILYSIN 10 U, POLVO Y DISOLVENTE PARA SOLUCION INYECTABLEActavis Group Ptc Ehf.
- United KingdomRapilysin 10unit powder and solvent for solution for injection vialsActavis UK Ltd
- IrelandRapilysin 10 U powder and solvent for solution for injection.Actavis Group hf
- NetherlandsRapilysin 10 U, poeder voor injectievloeistof 10 UActavis Group PTC ehf
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9980d24d-2106-4b75-bf75-f0bbe3dbd9d7 GET /v1/drugs/9980d24d-2106-4b75-bf75-f0bbe3dbd9d7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań",
"source": "urpl",
"strength": "10 j.m./ml",
"packaging": "05909990000593 ¦ Rpz ¦ EU/1/96/018/001 ¦ 23750\n2 fiol. 10 j.m. proszku + 2 amp.-strzyk. 10 ml rozp. + 2 przyrządy do sporz. roztw. + 2 igły",
"substance": "Reteplasum 10 j.",
"common_name": "Reteplasum",
"pl_product_id": "100125566",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": "2024-01-26"
}See everything about reteplase.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.